Nicolò Matteo Luca Battisti

Dr. Nicolò Matteo Luca Battisti

The Royal Marsden NHS Foundation Trust, London, City of London, UK
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in The Lancet Oncology
Verified
Journal Article
Open access
ALAlexander R Lyon
Alexander R Lyon
NYNadia Yousaf
Nadia Yousaf
Nicolò Matteo Luca BattistiNicolò Matteo Luca Battisti
Nicolò Matteo Luca Battisti
JMJavid Moslehi
Javid Moslehi
JLJames Larkin
James Larkin
Immune checkpoint inhibitors are a new class of anticancer therapies that amplify T-cell-mediated immune responses against cancer cells. Immune checkpoint inhibitors have shown important benefits in phase 3 trials, and several agents have been approved for specific malignancies. Although adverse events from immune checkpoint inhibitors are a common occurrence, cardiotoxic effects are uncommon, but are often serious complications with a relatively high mortality. Most cardiotoxic effects appear to be inflammatory in nature. Clinical assessment of a combination of biomarkers, electrocardiography, cardiac imaging, and endomyocardial biopsy can be used to confirm a possible diagnosis. In this Review, we discuss the epidemiology of immune checkpoint inhibitor-mediated cardiotoxic effects, as well as their clinical presentation, subtypes, risk factors, pathophysiology, and clinical management, including the introduction of a new surveillance strategy.

1 February 2018 in Journal of Oncology Practice
Verified
Journal Article
Closed access
KLKah Poh Loh
Kah Poh Loh
ESEnrique Soto-Pérez-De-Celis
Enrique Soto-Pérez-De-Celis
THTina Hsu
Tina Hsu
NGNienke de Glas
Nienke de Glas
Nicolò Matteo Luca BattistiNicolò Matteo Luca Battisti
Nicolò Matteo Luca Battisti
HWHans Wildiers
Hans Wildiers
Aging is a heterogeneous process. Most newly diagnosed cancers occur in older adults, and it is important to understand a patient’s underlying health status when making treatment decisions. A geriatric assessment provides a detailed evaluation of medical, psychosocial, and functional problems in older patients with cancer. Specifically, it can identify areas of vulnerability, predict survival and toxicity, assist in clinical treatment decisions, and guide interventions in routine oncology practice; however, the uptake is hampered by limitations in both time and resources, as well as by a lack of expert interpretation. In this review, we describe the utility of geriatric assessment by using an illustrative case and provide a practical approach to geriatric assessment in oncology.

1 September 2017 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
ESEnrique Soto-Pérez-De-Celis
Enrique Soto-Pérez-De-Celis
NGNienke de Glas
Nienke de Glas
THTina Hsu
Tina Hsu
RKRavindran Kanesvaran
Ravindran Kanesvaran
CSChristopher Steer
Christopher Steer
AHArti Hurria
Arti Hurria


1 July 2015 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
ALAndrea Luciani
Andrea Luciani
Laura BiganzoliLaura Biganzoli
Laura Biganzoli
GCGiuseppe Colloca
Giuseppe Colloca
CFCristina Falci
Cristina Falci
BCBruno Castagneto
Bruno Castagneto
PFPaolo Foa
Paolo Foa

1 November 2020 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
Nicolò Matteo Luca BattistiNicolò Matteo Luca Battisti
Nicolò Matteo Luca Battisti
AMAnna Rachelle Mislang
Anna Rachelle Mislang
LCLisa Cooper
Lisa Cooper
AOAnita O'Donovan
Anita O'Donovan
RARiccardo A. Audisio
Riccardo A. Audisio
HWhans wildiers
hans wildiers